Geneos Wealth Management’s Braskem BAK Stock Holding History

Geneos Wealth Management’s Portfolio BAK Stock Details BAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-12,556	Closed	-$305K	–	2404
2018 Q4	$305K	Buy	+12,556	New	+$341K	0.02%	480

Other funds holding BAK

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CCM

Contrarian Capital Management Greenwich, Connecticut $357M AUM 18.27% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

MCM

Moore Capital Management New York $4.92B AUM 35.41% 1-Year Est. Return

Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Geneos Wealth Management's BAK Position: Q1 2019 in Review

Geneos Wealth Management sold out of Braskem (BAK) in Q1 2019, closing a stake of 12,556 shares — an estimated $305K sold.

Geneos Wealth Management first reported a position in BAK in Q4 2018 and held it in 1 quarter. The position peaked at $305K in Q4 2018. 100 funds tracked by Wall St. Rank hold BAK as of Q1 2019.

Geneos Wealth Management reported no remaining Braskem position as of Q1 2019 after selling out during the quarter.
Geneos Wealth Management sold 12,556 Braskem shares in Q1 2019, an estimated $305K.
Geneos Wealth Management first reported a position in Braskem in Q4 2018 and held it in 1 quarter.
Geneos Wealth Management's Braskem position peaked at $305K in Q4 2018.
100 funds tracked by Wall St. Rank held Braskem as of Q1 2019.

Based on Geneos Wealth Management's 13F filing for Q1 2019, filed 7 Sep 2021.